Awards
EIT Health Finalist
Wonderful to be named as a 2024 finalist in the EIT Health Catapult Competition. From 100s of companies considered ➡️ to 30 semi-finalists ➡️ to
Wonderful to be named as a 2024 finalist in the EIT Health Catapult Competition. From 100s of companies considered ➡️ to 30 semi-finalists ➡️ to
Our recently published clinical validation study marks what we hope is a landmark moment for breast cancer patients and physicians all around the world. The
London, UK – 24 January 2024. A clinical validation study for Digistain’s novel, rapid and cost-effective alternative to transcriptomic risk profiling in order to efficaciously
We are the finalists of Health Tech Challengers 2023. Join us at the event
We take pride in our involvement with SpinOff Bulgaria, a program dedicated to nurturing innovation and promoting entrepreneurial spirit.
Delighted to have been selected by EIT Health as a semi-finalist. Wonderful to be recognised for our groundbreaking work in advancing breast cancer biomarker analytics.
LONDON – 19 JULY 2023: A revolutionary breast cancer diagnostic technology could save the NHS £287 million if adopted, a new study has found.
We are presenting a poster at the ESMO Breast Cancer Annual Congress (#ESMOBreast23) from 11-13 May in Berlin. The poster demonstrates that the Digistain Prognostic
Team Digistain with Prof Sir Mike Dixon OBE at the American Society of Breast Surgeons Annual Symposium this year where we were honored to be
Honoured today to be offered a place on NHS Oxford’s UK Access Program! A great step towards achieving even further adoption in the UK and
Delighted to be shortlisted as a finalist at the Medilink Business Awards 2023 for not one but two categories! Advances in Digital Health and for
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.
